The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients.

cancer survivors colorectal cancer diabetes mellitus multiple primary neoplasms second primary malignancies second primary neoplasms

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 16 06 2020
accepted: 09 12 2020
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 16 2 2021
Statut: epublish

Résumé

All colorectal cancer (CRC) survivors have an increased risk of developing second primary malignancies (SPMs). The association between diabetes mellitus (DM) and the risk of cancer is well known. However, the role of DM and its therapy in the development of SPMs in CRC patients is not well described. In this single-institutional retrospective analysis we identified 1,174 colorectal carcinoma patients, median follow-up 10.1 years, (median age 63 years, 724 men). All patients over 18 years with histologically confirmed CRC who were admitted in the period 1.1. 2003- 31.12.2013 and followed-up till 31.12. 2018 at the Masaryk Memorial Cancer Institute (MMCI) were screened for eligibility. The exclusion criteria were CRC diagnosed at autopsy, lost to follow-up and high risk of development of SPMs due to hereditary cancer syndrome. Tumours are considered multiple primary malignancies if arising in different sites and/or are of a different histology or morphology group. Comparisons of the basic characteristics between the patients with SPM and the patients without SPM were performed as well as comparison of the occurrence of SPMs by the site of diagnosis between the DM and non-DM cohorts and survival analyses. A SPM was diagnosed in 234 (20%) patients, DM in 183 (15%) patients. DM was diagnosed in 22.6% of those with SPM vs. in 13.8% of those without SPM (p=0.001). The most common types of SPMs in DM patients were other CRC, kidney, lung, bladder and nonmelanoma skin cancer, but only carcinoma of the liver and bile duct tracts was significantly more common than in the group without DM. Although breast cancer was the second most common in the group with DM, its incidence was lower than in the group without DM, as well as prostate cancer. A significantly higher incidence of SPMs was found in older CRC patients (≥ 65 years) and in those with lower stage colon cancer and DM. No significant difference in DM treatment between those with and without a SPM was observed including analysis of type of insulin. CRC patients with diabetes mellitus, especially those with older age, and early stages of colon cancer, should be screened for second primary malignancies more often than the standard population. Patients without DM have longer survival. According to the occurrence of the most common second malignancies, a clinical examination, blood count, and ultrasound of the abdomen is appropriate, together with standard breast and colorectal cancer screening, and lung cancer screening under certain conditions, and should be recommended in CRC survivors especially in patients with intercurrent DM, however the necessary frequency of screening remains unclear.

Identifiants

pubmed: 33585194
doi: 10.3389/fonc.2020.573394
pmc: PMC7878972
doi:

Types de publication

Journal Article

Langues

eng

Pagination

573394

Informations de copyright

Copyright © 2021 Halamkova, Kazda, Pehalova, Gonec, Kozakova, Bohovicova, Slaby, Demlova, Svoboda and Kiss.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Expert Opin Drug Saf. 2013 Mar;12(2):247-63
pubmed: 23394441
Arch Physiol Biochem. 2010 May;116(2):73-8
pubmed: 20199195
Diabetologia. 2009 Sep;52(9):1971-3
pubmed: 19609501
Eur J Cancer Prev. 2019 May;28(3):159-166
pubmed: 29668653
Endocr Relat Cancer. 2009 Dec;16(4):1103-23
pubmed: 19620249
J Clin Pharm Ther. 2019 Aug;44(4):588-594
pubmed: 31293011
Diabetes Metab Syndr. 2011 Oct-Dec;5(4):211-3
pubmed: 25572765
Diabetologia. 2009 Dec;52(12):2499-506
pubmed: 19756478
Eur J Cancer. 2016 Jan;52:19-25
pubmed: 26630530
Diabetes Care. 2014;37(5):1360-6
pubmed: 24574355
Mutat Res Genet Toxicol Environ Mutagen. 2018 Mar;827:1-8
pubmed: 29502733
Diabetologia. 2012 Jan;55(1):51-62
pubmed: 21956710
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
Int J Surg. 2014;12(6):587-93
pubmed: 24802517
Lancet Oncol. 2016 Apr;17(4):475-483
pubmed: 26947328
Oncotarget. 2017 Feb 28;8(9):16017-16026
pubmed: 27926481
Cancer Manag Res. 2019 Mar 01;11:1969-1983
pubmed: 30881122
Metabolism. 2013 Jul;62(7):922-34
pubmed: 23419783
Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61
pubmed: 20947488
Diabetes Metab. 2012 Dec;38(6):485-506
pubmed: 23159131
Breast Cancer Res Treat. 2011 Jan;125(2):545-51
pubmed: 20625814
Oncotarget. 2017 Mar 14;8(11):18456-18485
pubmed: 28060743
J Clin Oncol. 2014 Dec 10;32(35):4004-11
pubmed: 25267739
Oncologist. 2015 May;20(5):546-53
pubmed: 25802404
BMC Cancer. 2012 Aug 23;12:364
pubmed: 22917080
Oncologist. 2020 Apr;25(4):e644-e650
pubmed: 31943509
Diabetes Care. 2013 Aug;36 Suppl 2:S240-4
pubmed: 23882052
J Carcinog. 2011 Mar 17;10:6
pubmed: 21483654
Conn Med. 1992 Aug;56(8):411-4
pubmed: 1526142
Oncotarget. 2017 Jun 20;8(25):41132-41142
pubmed: 28456789
Clin Cancer Res. 2010 Mar 15;16(6):1695-700
pubmed: 20215559
Nutr Metab Cardiovasc Dis. 2018 May;28(5):436-443
pubmed: 29609864
Physiol Rev. 2015 Jul;95(3):727-48
pubmed: 26084689
Eur J Cancer Prev. 2005 Aug;14(4):307-8
pubmed: 16030420
Intest Res. 2015 Apr;13(2):145-52
pubmed: 25931999
Ann Surg Oncol. 2019 Jul;26(7):2037-2043
pubmed: 30949861
Curr Drug Saf. 2013 Nov;8(5):333-48
pubmed: 24215311
Klin Onkol. 2015;28(1):30-43
pubmed: 25692753
Acta Oncol. 2016 Jul;55(7):851-8
pubmed: 27150973
Chest. 2005 Apr;127(4):1152-8
pubmed: 15821189
Clin Sci (Lond). 2012 Mar;122(6):253-70
pubmed: 22117616
Oncotarget. 2015 Nov 3;6(34):36441-55
pubmed: 26497364
Ann Oncol. 2016 Dec;27(12):2184-2195
pubmed: 27681864
J Clin Oncol. 2012 Oct 20;30(30):3734-45
pubmed: 23008293
Diabetologia. 2017 Sep;60(9):1691-1703
pubmed: 28573394
Diabetes Care. 2013 Feb;36(2):294-301
pubmed: 22966091
Oncotarget. 2017 Apr 11;8(15):25242-25250
pubmed: 28445955
Diabetes Care. 2011 Sep;34(9):1965-71
pubmed: 21775752
Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):525-530
pubmed: 29716927
Endocr Rev. 2001 Oct;22(5):706-17
pubmed: 11588149
Diabetes Care. 2016 Mar;39(3):486-94
pubmed: 26740633
J Endocrinol Invest. 2016 Dec;39(12):1365-1376
pubmed: 27368923
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
Medicine (Baltimore). 2015 Jul;94(26):e1079
pubmed: 26131831

Auteurs

Jana Halamkova (J)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czechia.
Department of Medical Ethics, Faculty of Medicine, Masaryk University, Brno, Czechia.

Tomas Kazda (T)

Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czechia.
Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czechia.

Lucie Pehalova (L)

Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.
Faculty of Medicine, Masaryk University, Brno, Czechia.

Roman Gonec (R)

Department of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czechia.

Sarka Kozakova (S)

Department of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czechia.

Lucia Bohovicova (L)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.

Ondrej Slaby (O)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czechia.
Central European Institute of Technology, Molecular Oncology II-Solid Cancer, Masaryk University, Brno, Czechia.

Regina Demlova (R)

Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
Clinical Trial Unit, Masaryk Memorial Cancer Institute, Brno, Czechia.

Marek Svoboda (M)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czechia.

Igor Kiss (I)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czechia.
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czechia.

Classifications MeSH